Last Updated on January 12, 2025 by The Health Master
Aurobindo Pharma Ltd said its wholly-owned subsidiary APL Healthcare has received a final approval from the US health regulator for generic Sevelamer hydrochloride tablets.
Sevelamer hydrochloride tablet is used to control serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
The approval granted by the US Food & Drug Administration (USFDA) to manufacture and market Sevelamer hydrochloride is for tablets of strengths 400 mg and 800 mg, Aurobindo Pharma said in a regulatory filing.
These tablets are bioequivalent and therapeutically equivalent to the reference listed drug Renagel tablets, 400 mg and 800 mg of Genzyme Corporation, it added.
The approved product has an estimated market size of around USD 37 million for the twelve months ending May 2023, the company said citing IQVIA data.
USFDA gives nod to this Nasal spray for Vitamin B12 deficiency
USFDA approves drug for growth hormone deficiency in kids
USFDA approves this drug to treat hair loss
USFDA gives approval for Tiotropium dry powder inhaler
USFDA gives approval for generic acne-treating drug
USFDA gives final nod for Varenicline Tablets
Govt to establish recruitment Rules for Medical Device Officers
DCGI gives approval for Dupilumab to treat Atopic Dermatitis
Stringent action to be taken against companies that make spurious drugs: HM
USP establishes Program Unit Team on testing of Excipients
Major fire breaks out at Govt’s medicine godown: Odisha
CDSCO to streamline Drug Regulations for Quality and Patient Safety
Pharma Cleanrooms: Ensuring compliance with GMP
Bulk Drug Park at Una to boost Pharma ecosystem: CM
DCOIWA: A grand success of 1st Annual Congress Cum Workshop held at Delhi
